Home Oxygen Concentrator Recalls: 44 FDA CAW Records and 11 Class I Actions

Executive Summary

Home oxygen concentrators are among the few medical devices that run continuously in patients' homes while enriching the surrounding atmosphere with oxygen — a combination that makes fire the defining product-risk theme. Our analysis of FDA records for CAW — Generator, Oxygen, Portable finds a category whose post-market signature is dominated by three recurring failure modes:

• 44 FDA recall records sit under product code CAW; 33 have matching FDA enforcement classifications, including 11 Class I actions
• Electrical/power faults, fire/thermal faults, and low oxygen purity/output failures dominate the classified record — these categories overlap because the most serious capacitor and power-supply faults can both ignite and interrupt oxygen delivery
• Nidek Medical drives the largest share of the most-serious actions: 9 of the 11 classified Class I CAW records list Nidek Medical Products as the recalling firm, almost all citing "capacitor failure may result in a fire hazard and loss of supplemental oxygen"; the remaining two Class I CAW records are Jiangsu Jumao X-Care's TruAire-5 recall and Medical Depot / Drive DeVilbiss's iGo2 car-adapter recall
• The MAUDE record is the largest of any respiratory home-care device category we track: 52,664 device reports under CAW, including 517 death reports and 1,095 injury reports, with Invacare Florida Operations alone named on 46,136 reports

For quality, regulatory, and home-medical-equipment teams, the takeaway is that concentrator recall risk is overwhelmingly a thermal-electrical and oxygen-delivery-purity problem, concentrated in a small group of legacy manufacturers (Invacare, Nidek, Caire, and DeVilbiss) whose installed base defines the category's post-market footprint.

Why Oxygen Concentrators Carry a Distinct Risk Profile

A home oxygen concentrator separates nitrogen from room air using a molecular-sieve (zeolite) bed, delivering up to 95% oxygen to a patient who is often on therapy continuously. Two physics facts shape the device's entire post-market record: oxygen vigorously supports combustion, and a patient who depends on supplemental oxygen can be harmed by both fire and by a silent drop in delivered purity.

The fire risk is not theoretical. The National Fire Protection Association estimates that during 2017–2021, oxygen-administration equipment was involved in an average of 228 home fires per year reported to local fire departments, resulting in an average of 96 civilian deaths and 106 civilian injuries per year — and roughly one in every three of those home fires was fatal (NFPA, "Fires and Burns Involving Home Medical Oxygen"). These are fire-department-reported events that capture the downstream consequence of an ignition in an oxygen-enriched home; they are a separate population from the device-fault reports in MAUDE, but together they bracket the same risk. The clinical literature on home-oxygen fires reports comparable severity, with a case series mortality around 10% and elderly smokers the over-represented group (Home oxygen and domestic fires, PMC).

The product code at the center of this analysis is CAW — Generator, Oxygen, Portable, a Class II device under the Anesthesiology medical-specialty panel. Adjacent oxygen-delivery product codes exist, including oxygen conservers, liquid-oxygen units, oxygen cylinders, ventilators, anesthesia systems, and membrane oxygenators, but those are outside this article's device scope.

The concentrator (CAW) is the product code used for the recall, MAUDE, and 510(k) records below. This CAW-only scope avoids counting ventilator, anesthesia-system, oxygenator, or cylinder-regulator recalls merely because their reason-for-recall text mentions oxygen, oxygen desaturation, or a third-party oxygen concentrator.

Data Source and Method

• Sources: FDA Medical Device Recall database (CAW recall-initiation records), FDA device enforcement report database (Class I/II/III classification linked by recall number where available), FDA MAUDE adverse-event database (device reports by product code), and FDA 510(k) database (clearances by product code)
• Analysis sample: 44 FDA recall records under product code CAW; 33 matching enforcement records with Class I/II/III classification; 52,664 MAUDE device reports under CAW; 286 510(k) clearances under CAW
• Run date: 2026-06-20
• Method: All counts were computed by MedDeviceGuide from the public FDA recall, enforcement, MAUDE, and 510(k) extracts using product code CAW as the primary scope. Enforcement records were linked back to CAW recall records by recall number when a matching enforcement entry was available. Records for non-CAW products were excluded even when the reason-for-recall text mentioned oxygen, oxygen desaturation, or a third-party oxygen concentrator. The CAW recall and 510(k) samples contain no Baxter or Getinge recalling-firm/applicant records. Firm names are reproduced as recorded by FDA. Root-cause themes were tallied from reason-for-recall text and are not mutually exclusive. MAUDE death and injury counts are as-filed report counts and do not by themselves establish that the device caused the outcome.

The Enforcement Footprint: 11 Classified Class I Actions

The FDA recall database contains 44 CAW recall records. Of those, 33 have a matching enforcement entry with a populated FDA classification. The classified subset breaks down as follows:

The 11 historical CAW recall records without a matching openFDA enforcement classification were kept in the recall-count analysis, but excluded from the class-share denominator. A one-third Class I share within the classified CAW subset is still high for a Class II device family and reflects the dual fire-and-suffocation hazard: a concentrator that ignites, or one that silently stops producing therapeutic oxygen, can both cause death in a home setting where the patient may be alone and where there is no clinical staff to intervene.

Class I: A Nidek-Dominated Fire Record

The Class I record is the core of the concentrator safety story. Of the 11 classified Class I CAW actions, the recalling firms are:

Nidek's nine Class I actions share an almost identical reason statement: "capacitor failure may result in a fire hazard and loss of supplemental oxygen." That single component-failure mode — a capacitor that both ignites and cuts oxygen delivery — is the most concentrated Class I pattern in the entire concentrator record. The recent Class I actions extend the fire theme to newer entrants and importers:

• Jiangsu Jumao X-Care TruAire-5 (Class I, correction letter November 2024; FDA-posted February 2025) — the concentrator "may melt or catch on fire during use," with all units in a defined serial-number range (Model O2C5L, JA2311000001–JA2312000740) ordered removed from service and returned to Compass Health Brands (Health Exec, 2025; FDA/MEHCA, 2025)
• Medical Depot (Drive DeVilbiss) iGo2 portable concentrator car adapter (Class I, May 2025) — "potential for DC Power Supply housing to become hot to the touch and deform the plastic housing," with affected charger cords ordered destroyed (Healthcare Brew, 2025)

These recent actions fit the established pattern: the ignition source varies (a capacitor, a power-supply housing, an unknown spontaneous-combustion cause), but the oxygen-enriched operating environment is what turns a routine electrical fault into a Class I event.

Root Causes: Power, Fire, and Purity

Tallying reason-for-recall text across the 33 classified CAW enforcement records produces a hierarchy that mirrors the device's underlying physics. Categories are not mutually exclusive; the Nidek capacitor actions, for example, are both electrical/power faults and fire/loss-of-oxygen events.

The electrical/power and fire/thermal buckets overlap heavily because a single component fault can create both ignition risk and oxygen-delivery interruption. The low-purity bucket describes the silent-suffocation pathway. A representative purity-failure reason comes from Ohio Medical: "erroneous calibration values, potentially resulting in: as the device ages, oxygen purity will gradually decrease" — a defect that produces no fire and may not be visible to a home patient until symptoms appear.

The MAUDE Record: 52,664 Reports

The MAUDE adverse-event database shows the concentrator category's post-market scale. Under CAW, we count 52,664 device reports, including 517 reports in which a patient death was recorded, 1,095 injury reports, and 50,841 malfunction reports. (MAUDE reports are filed voluntarily and by manufacturers under MDR obligations; a death report does not by itself establish device causation, and oxygen-therapy patients are often seriously ill, but the volume is the relevant benchmark for category-level surveillance.)

Annual report volume has risen steadily through the post-pandemic period:

The brand-level distribution is dominated by Invacare's home-concentrator platforms:

By exact manufacturer name, Invacare Florida Operations alone is named on 46,136 of the 52,664 reports — roughly 88% of the CAW MAUDE footprint — followed by Respironics, Inc. (933), Inogen, Inc. (354), DeVilbiss Healthcare LLC (326), and Caire Inc. (214). The PerfectO2 and Platinum lines are Invacare's flagship home concentrators; their dominance of the MAUDE record is a function of a very large installed base rather than necessarily a higher per-unit failure rate, but it means that Invacare's product decisions and recall history effectively set the category's safety baseline.

The Recall Record: Concentration and Recurrence

The FDA recall-initiation database records 44 CAW recalls, with the recalling firms again concentrated in the legacy manufacturers:

Recall activity clusters in several periods — nine recall records posted in 2012, four in 2024, four in 2025, and one already in 2026 — suggesting a cyclical rather than monotonically declining pattern. The same firm names recur across decades: Nidek, Caire, Invacare, and DeVilbiss appear in both legacy and recent records, indicating that some root causes (capacitor reliability, battery/power reliability, sieve-bed purity drift) have persisted across product generations.

The 510(k) Entry Record: A Mature, Concentrated Market

We count 286 510(k) clearances under CAW, the largest clearance record of any respiratory home-care device category we have analyzed. The clearance pathway is overwhelmingly Traditional (259 Traditional, 18 Special, 9 Abbreviated). The applicant field is dominated by the same firms that appear in the recall and MAUDE records:

Clearance activity has picked up recently — eight in 2023, 12 in 2025, and three in the first half of 2026 — partly reflecting new portable-concentrator entrants and partly replacement clearances as firms refresh platforms after the 2021 Philips Respironics recall reshaped the respiratory-device market. The combination of a large, decades-old clearance base and recurring power, fire, and purity recalls means that concentrator post-market risk is effectively the post-market risk of a small number of long-running platforms from Invacare, Nidek, Caire, DeVilbiss, and newer portable-concentrator entrants.

What This Means for Quality, Regulatory, and Home-Medical-Equipment Teams

The data supports four practical takeaways:

1. Design for the oxygen-enriched environment first. Electrical/power faults and fire/thermal faults are the leading Class I drivers; capacitor and power-supply component qualification, flame-retardant housings, and thermal cutoffs are where the highest-severity post-market exposure is created or avoided for this family.
2. Treat oxygen-purity monitoring as a life-critical function, not a comfort feature. The low-purity failure mode is silent — no fire, often no alarm — and the calibration-drift pattern means periodic verification of delivered oxygen concentration is a core risk control, especially for aging units in the field.
3. Track the installed base, not just the current catalog. Because Invacare, Caire, Nidek, and DeVilbiss recall and MAUDE records span decades of platforms, a home-medical-equipment provider's effective concentrator safety exposure is defined by its service and rental fleet, including legacy units still in patient homes.
4. Benchmark against the recent baseline. MAUDE report volume has roughly quadrupled from 2018 to 2025, and Class I actions continue into 2025; a long-run average understates current concentrator recall risk.

Home oxygen concentrators will remain a focus of FDA enforcement for as long as they enrich the atmosphere around a patient while running unattended. The public data — 44 CAW recall records, 11 classified Class I actions, and 52,664 MAUDE reports — is the evidence base, and the consistent answer is fire, electrical faults, and silent purity loss.

Data sources: FDA device enforcement report database, FDA Medical Device Recall database, FDA MAUDE adverse-event database, and FDA 510(k) database; analysis by MedDeviceGuide, run date 2026-06-20. Root-cause themes are derived from FDA reason-for-recall text and are not mutually exclusive. MAUDE death and injury counts are as-filed report counts and do not establish device causation. This article is educational and is not regulatory, quality-system, or clinical advice for a specific product.